Slide 1: Commercialising non-invasive cardiac monitoring technology
For personal use only Commercialising non-invasive cardiac monitoring technology Rob Phillips MPhil(med), FASE, DMU(cardiol) Chief Executive Officer November 2012
Slide 2: Who we are and what we do
Who we are and what we do… For personal use only • Publicly listed bioscience company with world leading cardiovascular monitoring technology • Focused on commercialising non-invasive USCOM 1A • 10 years + $18 million proving accuracy, safety and efficacy • Cleared by US Food & Drug Administration (
Slide 3: USCOM1A cardiac monitor
USCOM1A cardiac monitor For personal use only Non invasive, accurate, compact platform technology Cardiac output Works with all other hospital equipment Stroke volume Heart rate Intuitive touch screen Systemic vascular resistance Real time data Left and right heart measurement Non invasive, real tim
Slide 4: Selected financial snapshot FY2012
Selected financial snapshot FY2012 For personal use only 5-year revenues 6-month share price ASX: UCM $ thousands Market cap: $11 million 13 Nov 0.18 Shares on issue: 63 million 0.17 FY2012 product sales: $0.8 million 0.16 Cash @ 30 Sept ‘12: $1.16 million 0.15 0.14 Top 20 holders: 80% 0.13 0.12 Maj
Slide 5: Where we are today
Where we are today For personal use only • Successful capital raising in September 2012 ($1.2 million @ 12 cents) • Sales of $800,000 in FY2012 with quarterly cash burn of $300,000 • Current customers - hospital peadiatric, neonatal and adult intensive care units, emergency departments and anesthesi
Slide 6: Foundations for growth: clinical data
Foundations for growth: clinical data For personal use only • Uscom has invested in building a large body of clinical evidence used to support global marketing and sales • 250 peer reviewed publications to date – with more coming! • Multi-application platform technology • New data expands product ap
Slide 7: Platform technology - Strategic partnerships
Platform technology - Strategic partnerships Pharmaceuticals For personal use only Ultrasound CO module Crit Care CO Monitoring module Home care Ventilation CO module Hypertension, HF and sleep monitoring Pacemaker optimisation unit ‐ ElectroCOM Mobile Monitoring module 7 The measure of life www.usc
Slide 8: Foundations for growth: market opportunities
Foundations for growth: market opportunities For personal use only • Investment in clinical data is designed to support expanded use for a range of major medical needs worldwide • New markets (currently un-partnered) • Hypertension • Congestive Heart failure • Sepsis • Pregnancy hypertension • Elect
Slide 9: Foundations for growth: commercial partners
Foundations for growth: commercial partners For personal use only • Wide reaching patents across many applications • Potential to add value to established technologies in major markets • Active discussions with a number of potential strategic partners globally Market UCM product Potential commercial
Slide 10: Case study: How clinical data drives sales
Case study; How clinical data drives sales… For personal use only • 6 year study at Bathurst Hospital demonstrating reduction in sepsis mortality and and hospital costs using USCOM1A • Mortality reduced 93% (from 60.7% to 4.4%) • Renal failure reduced 95% (52.7% to 2.6%) • Emergency transports reduc
Slide 11: 2006-2012 practice changing Sepsis result
Case study; How clinical data drives sales… For personal use only 2006-2012 practice changing Sepsis result Hospital sepsis mortality – down 95% 30 Bathurst USCOM NSW 25 NSW Rural Australia 20 Australian Rural 15 10 5 0 2006 2007 2008 2009 2010 2011 2012 ANZICS CORE practice audit data 11 The measur
Slide 12: Foundations for growth: R&D pipeline
Foundations for growth: R&D pipeline For personal use only A platform technology with multiple applications Current products • USCOM 1A – Advanced haemodynamics • OXYCOM – Real time Oxygen Delivery (DO2) • USCOMt – Haemodynamics transducer • CareCOM – Physiology mapping and treatment guide • EduCOM
Slide 13: Foundations for growth: Patented R&D pipeline
Foundations for growth: Patented R&D pipeline For personal use only Small, Telemetric, Continuous, Portable, USCOM App 13
Slide 14: Foundations for growth: efficient operations
Foundations for growth: efficient operations For personal use only • USCOM1A product currently sells for $30,000 per unit • All manufacturing and development in Sydney • Production team able to produce 80 units per month • Currently establishing new additional skills and capabilities to expand the S
Slide 15: What's next in 2013?
What’s next in 2013? For personal use only • Grow global revenues from direct sales • Advance current strategic and commercial partnership discussions with focus on licensing and revenues • Continue to build clinical and economic evidence around treatment of major medical conditions • R&D focus to e
Slide 16: Summary
Summary For personal use only • Commercially focused, revenue generating medical device company • World-leading technology transforming inefficient medical practice • Aim to create another world-class Australian medical device business • Strong competitive position • Leveraging outstanding science i
Slide 17: Thank you
USCOM For personal use only Thank you Rob Phillips Chief Executive Officer T: (02) or +61 418681154 E: rob@uscom.com.au 17 The measure of life www.uscom.com.au
Slide 18: Appendicies
For personal use only 18 Appendicies
Slide 19: USCOM1A has competitive advantages
USCOM1A has competitive advantages For personal use only Rel+Re Non- SV beat Method Manufacturer Technology p invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Sonosite BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ De
Slide 20: ICU cardiac monitoring market
ICU cardiac monitoring market For personal use only Worldwide market Cap value at 25% estimate ($30k- penetration, 50% Department Total beds* (US) 1/10beds) profit and x20PE Neonatal ICU 17,000 $51m $128m Paediatric ICU 4,000 $12m $30m Cardiac Surgery 10,000 $30m $75m Adult ICU 50,000 $150m $375m To
Slide 21: Cardiac monitoring landscape
Cardiac monitoring landscape For personal use only Clinical assessment • BP, HR, colour, reperfusion time etc. Inaccurate Non-invasive • USCOM – Transcutaneous CW Doppler safe, accurate, effective • ICG – Bio-impedance inaccurate and unproven • Tonometry – Transcutaneous APP BP measure and difficult
Slide 22: What the experts say...
What the experts say... For personal use only “This machine is saving lives, there are no two ways about it” Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, Bathurst Base Hospital, N.S.W. Dept of Health, Australia “The USCOM device is a simple method of accurately and noni
Slide 23: Potential value of product partnerships
Potential value of product partnerships For personal use only Potential annual market $ millions • Partnership with instant take up of technology • Four new markets • 50% profit share • 20% penetration • No upgrades • USCOM gross $84million p.a. • Cap value = 15xPE (84) = $1260 million • 60 million
Slide 24: Cardiac monitoring investment landscape
Cardiac monitoring investment landscape For personal use only Investment opportunity Capitalised value of USCOM and current competitors, $ millions • Last capital raising $0.12 • Current price $0.17 • Equivalent price to mean competitors ($65m) with 60m shares on issue$1.05 24